As sustainability becomes a core focus for biotech, there is a growing need for professionals who can implement eco-friendly practices in biomanufacturing while ensuring regulatory compliance. This ...

The biotechnology sector is experiencing a surge in innovative ventures, requiring leaders who can navigate complex business strategies and help build successful businesses. This certificate addresses ...

Interested in transforming breakthrough research into real-world therapies? This session introduces the MS/MBA Biotechnology Program — designed for life scientists who want to lead in biotech, pharma, ...

The Harvard University Graduate School of Arts and Sciences in Cambridge, Mass., and Harvard Business School in Boston recently unveiled a new joint master’s degree program in the life sciences. The ...

Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. | Contineum Therapeutics’ M1 receptor ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

Tell us about your life before HBS. I grew up in Antwerp, Belgium as part of the Jewish community. Having four grandparents who are Holocaust survivors, I felt it was important to experience life in ...

Shares of US clinical-stage biotech Contineum Therapeutics were down 8.7% at $11.16 in pre-market activity today, after it ...

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ms. Zhao Yan, president and general manager of Bloomage Biotech, shared her insights on how emerging biotechnologies can contribute to the achievement of ...

Longevity Biotech, Inc. (LBT) has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society's commercial research funding program, to evaluate LBT-3627 in ...

The global biotechnology market was valued at more than $1.5 trillion in 2023. By 2030, that value is expected to balloon to nearly $4 trillion, according to Grand View Research. To help explain that ...

JERUSALEM, June 7 (Reuters) - Israel-based Teva Pharmaceutical Industries and Active Biotech AB said on Thursday they would start a clinical Phase III trial of relapsing multiple sclerosis drug ...